Biological Evaluation of Medical Devices: Understanding Key Standards for Safety and Compliance

In an era where patient safety, product quality, and regulatory demands are at the forefront of the health care industry, the biological evaluation of medical devices has become a critical business necessity. The ability to ensure that all devices—from everyday consumables to complex implants—are biocompatible and safe is central to public trust and commercial success. Four cornerstone standards, EN ISO 10993-10:2023, EN ISO 10993-1:2025, EN ISO 10993-17:2023, and EN ISO 10993-23:2021, together provide a comprehensive framework for evaluating the biological effects of medical devices. Their effective implementation ensures not only compliance with international legislation but also enhances productivity, strengthens risk management, enables business scaling, and maintains security and quality across product lines.

Overview / Introduction

Biomedical innovation has never advanced as rapidly as in recent years. As health care organizations introduce more sophisticated devices, ensuring their safety through rigorous biological evaluation is not just a regulatory requirement—it's a public health imperative. International standards provide both a scientific and practical roadmap for manufacturers, regulators, and users, ensuring that medical devices are evaluated consistently to minimize health risks.

Why are biological evaluation standards crucial?

• They make risk management a core part of product development
• They ensure market access by aligning with global regulations (EU, FDA, etc.)
• They support transparency and trust among patients, practitioners, and authorities
• They facilitate scaling by providing ownership of processes across organizations

In this guide, you'll learn about the scope, requirements, and direct business impact of four foundational standards for biological evaluation. Whether you're a manufacturer, quality manager, or just curious about how device safety is assured, this article unpacks the essentials in an easy-to-digest format.

Detailed Standards Coverage

EN ISO 10993-10:2023 – Biological Evaluation: Tests for Skin Sensitization

Biological evaluation of medical devices – Part 10: Tests for skin sensitization (ISO 10993-10:2021)

This standard addresses the assessment of medical devices and their materials for their potential to cause skin sensitization—a form of allergic reaction following repeated contact. The document outlines detailed procedures for in vivo testing using both murine (mouse) and guinea pig models, and it introduces a structured approach to selecting test methods and interpreting results.

What does it cover?

• Step-by-step in vivo experimental methods
• Preparation and selection of test samples, animal husbandry, result evaluation
• Guidance for interpreting sensitization data, including considerations for chemical composition and alternative (non-animal) methods
• How to report results in a standardized way

Who should comply?

• Medical device manufacturers
• Quality assurance teams in health care industries
• Laboratories conducting safety assessments

Practical implications: Compliance ensures that devices in contact with the skin—such as gloves, patches, and wearable sensors—meet safety criteria, reducing risks of allergic responses in patients and users.

Notable features:

• Incorporates the latest understanding of skin sensitization mechanisms
• Provides harmonization with EU General Safety and Performance Requirements (Regulation (EU) 2017/745)
• References preparation of materials, considerations for different material types, and options for non-animal testing

Key highlights:

• In vivo and alternative non-animal methods
• Focus on stepwise approach and practical interpretation
• Aligns with European regulatory requirements

Access the full standard:View EN ISO 10993-10:2023 on iTeh Standards

EN ISO 10993-1:2025 – Requirements and Principles for Biological Safety Risk Management

Biological evaluation of medical devices – Part 1: Requirements and general principles for the evaluation of biological safety within a risk management process (ISO 10993-1:2025)

This foundational standard provides the overarching framework for the biological evaluation of all medical devices. It establishes the general principles guiding safety assessments within the ISO 14971 risk management process and ensures that all risks associated with exposure to device constituents are identified and mitigated throughout the product’s lifecycle.

What does it cover?

• Requirements for integrating biological safety evaluation into risk management
• Detailed guidance on evaluation plans, hazard identification, and risk analysis
• Consideration of all modes of body contact (direct and indirect)
• Applicability to various device types (including personal protective equipment like gloves and masks)
• Covers stages from initial device design and clinical trials to end-of-life decommissioning

Who should comply?

• Medical device manufacturers (from early prototyping to post-market)
• Clinical research organizations and regulatory bodies
• Developers of personal protective equipment

Practical implications: Implementing this standard ensures that biological risks are considered and managed at every stage, supporting market approvals globally and streamlining clinical evaluations and trials.

Notable features:

• Cross-references other parts of the ISO 10993 series for specific testing (cytotoxicity, sensitization, irritation, etc.)
• Integrates with international regulatory frameworks for medical devices
• Supports both initial market introduction and lifecycle management

Key highlights:

• Risk management process integration (ISO 14971)
• Comprehensive evaluation across device life cycle
• Applicability to a wide range of device types

Access the full standard:View EN ISO 10993-1:2025 on iTeh Standards

EN ISO 10993-17:2023 – Toxicological Risk Assessment of Medical Device Constituents

Biological evaluation of medical devices – Part 17: Toxicological risk assessment of medical device constituents (ISO 10993-17:2023)

This standard provides a systematic process for assessing the toxicological risks of chemicals and other constituents that may be present in or released from medical devices. It supports determining whether exposure remains within levels considered safe for patients and users.

What does it cover?

• Stepwise toxicological risk assessment process, including hazard identification and exposure analysis
• Criteria and methods for deriving tolerable contact levels (TCL) and tolerable intake (TI)
• Margin of safety calculation and reporting
• Evaluation principles for carcinogens, mutagens, and chemicals with reproductive or endocrine-disrupting effects
• Integration with chemical characterization data (from ISO 10993-18)

Who should comply?

• Manufacturers involved in the development and validation of new devices
• Toxicology consultants and validation laboratories
• Regulatory affairs teams

Practical implications: Reduces the likelihood of device recalls and regulatory penalties by ensuring all leachable or extractable substances from device materials are subjected to recognized risk thresholds. Faster clearances and greater confidence in the safety of product launches are additional benefits.

Notable features:

• Considers current scientific evidence to set safe exposure benchmarks
• Explicitly excludes components that do not come in contact with the body and those already established as safe
• Encourages the use of modern risk estimation models

Key highlights:

• Science-based tolerable intake and margin of safety calculation
• Covers entire process from data gathering to risk acceptance
• Supports international regulatory submissions

Access the full standard:View EN ISO 10993-17:2023 on iTeh Standards

EN ISO 10993-23:2021 – Tests for Irritation

Biological evaluation of medical devices – Part 23: Tests for irritation (ISO 10993-23:2021)

EN ISO 10993-23:2021 standardizes test procedures for evaluating irritation potential of medical devices, materials, or their extracts. The tests predict and classify the device’s potential to cause irritation on contact, employing a combination of in silico, in vitro, and, where necessary, in vivo methods.

What does it cover?

• Pre-test considerations, including selection of appropriate test scenarios
• In vitro methods (such as reconstructed human epidermis models) for dermal exposure
• In vivo procedures for more complex exposures
• Criteria for classifying irritation potential
• Factors influencing interpretation (e.g., material types, chemical composition)

Who should comply?

• Designers and producers of devices with skin, mucosal, or other direct tissue contact
• Laboratories carrying out materials safety and compliance testing
• Quality assurance and regulatory personnel

Practical implications: Rise in wearable and skin-contacting medical technology makes irritation testing fundamental for protecting end-users from adverse reactions, assuring both patient safety and product credibility.

Notable features:

• Strong emphasis on reduction of animal testing (favors validated in vitro tests)
• Direct references to ISO 10993-1 process alignment
• Supports full lifecycle assessment and global regulatory harmonization

Key highlights:

• Stepwise approach combining in vitro and in vivo methods
• Interpretation framework for standardized results
• Coverage of both chemical and physical causes of irritation

Access the full standard:View EN ISO 10993-23:2021 on iTeh Standards

Industry Impact & Compliance

Implementing the EN ISO 10993 series offers significant benefits for businesses in the health care technology and medical device sectors. By adhering to internationally recognized standards, organizations can:

• Accelerate product approvals and market entry across major global regulatory regimes
• Reduce liability exposure and risk of costly recalls
• Build patient and practitioner trust through demonstrated safety
• Enhance internal productivity by integrating risk-based decision-making into product development
• Facilitate international scaling and collaborations through consistent, auditable processes

Risks of non-compliance can include:

• Regulatory penalties, product seizures, or forced market withdrawals
• Damage to brand reputation and stakeholder trust
• Increased rates of adverse events and post-market surveillance costs

Stakeholders ranging from manufacturers and importers to contract research organizations all benefit from a robust biological evaluation regime anchored in these standards.

Implementation Guidance

Getting started with biological evaluation standards means establishing a structured plan tailored to your organization and products. Here are best practices and actionable steps for smooth implementation:

1. Integrate early: Align standards with your design and development process from the outset, not just at regulatory milestones.
2. Establish a cross-functional team: Involve toxicologists, engineers, quality managers, and regulatory experts.
3. Use a phased risk assessment: Start with high-level hazard identification (per EN ISO 10993-1), then move to more detailed evaluations (e.g., sensitization, irritation, or toxicological risk) as needed.
4. Maintain thorough documentation: Capture testing protocols, decision rationales, and results in risk management files for easy auditability.
5. Invest in training: Equip your teams with up-to-date knowledge of current standards and best practices.
6. Leverage external expertise: Consult accredited testing laboratories and regulatory consultants for complex evaluations or new technologies.
7. Monitor and update: Keep up with updates to the EN ISO 10993 series; standards are regularly revised to reflect new science and regulations.

Resources for organizations:

• iTeh Standards (https://standards.iteh.ai): Reliable access to the latest standard editions and expert interpretations
• International and national regulatory bodies' training resources
• Industry consortia, networking events, and standards user groups

Conclusion / Next Steps

The biological evaluation of medical devices is not just a regulatory hurdle—it’s a foundational practice for protecting patient health, boosting organizational reputation, and accelerating business growth in a rapidly evolving marketplace. By adopting EN ISO 10993-10:2023, EN ISO 10993-1:2025, EN ISO 10993-17:2023, and EN ISO 10993-23:2021, organizations demonstrate their commitment to safety, compliance, and quality-backed innovation.

Key takeaways:

• Biological evaluation is an end-to-end process covering all product lifecycle stages
• These standards make compliance, risk management, and market expansion achievable and systematic
• Using harmonized procedures supports transparency, audit-readiness, and ongoing improvement

Ready to future-proof your device safety program?

• Explore the full standards on iTeh Standards
• Stay ahead by integrating biological evaluation into your organization’s core processes
• Join industry forums and keep your teams trained on the latest editions

Let safe, innovative, and scalable medical devices define your commitment to global health care excellence.

https://standards.iteh.ai/catalog/standards/cen/ce610ef5-e15d-41a9-b53b-87d5cef15ed7/en-iso-10993-10-2023https://standards.iteh.ai/catalog/standards/cen/763af65d-2b0f-4723-b012-0b88e93fb8f0/en-iso-10993-1-2025https://standards.iteh.ai/catalog/standards/cen/4f7f544e-9464-4bb1-b165-b5fa704d9cf4/en-iso-10993-17-2023https://standards.iteh.ai/catalog/standards/cen/f201ba84-b586-47df-952e-b001a06b7346/en-iso-10993-23-2021